Clinical trial
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to…
NCT00018018 · National Human Genome Research Institute (NHGRI), NIH · Completed
Key facts
| NCT number | NCT00018018 |
|---|---|
| Title | Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency |
| Official title | Treatment of SCID Due to ADA Deficiency With Autologous Cord Blood or Bone Marrow CD34+ Cells Transduced With a Human ADA Gene |
| Lead sponsor | National Human Genome Research Institute (NHGRI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Severe Combined Immunodeficiency Syndrome |
| Intervention type | Drug |
| Interventions | CD34+ cells transduced with ADA retrovir |
| Enrollment | 8 |
| Start date | Jun 20, 2001 |
| Completion | Sep 17, 2014 |
| First posted | Jun 28, 2001 |
| Last update posted | Dec 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: